Drug discovery for breast cancer and co-instantaneous cardiovascular disease: what is the future? "Therefore, the prevention and management of cardiovascular diseases for breast cancer patients is crucial and in urgent need to further promote survival and life quality, which needs to be performed not only in clinical care, but also in drug discovery."
作者： Lina Yin
DOI:
关键词:
摘要: It has been estimated that approximately 1.4 mil -lion people were diagnosed with breast cancer (BC) in 2008 worldwide, which accounted for 23% of newly identified cases. At the same time, 458,400 BC patients died, represent -ing 14% total cancer-related deaths. On other hand, 2012 250,000 new cases will emerge USA; while 39,510 die it
future-science.com 
researchgate.net 参考文章(20)
Karl T. Weber, C. G. Brilla, S. E. Campbell, E. Guarda, G. Zhou, K. Sriram, Myocardial fibrosis: role of angiotensin II and aldosterone Angiotensin and the Heart. ,vol. 88, pp. 107- 124 ,(1993) , 10.1007/978-3-642-72497-8_8
Muhammad Younus, Michelle Kissner, Lester Reich, Nicola Wallis, Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature. Drug Safety. ,vol. 34, pp. 1125- 1149 ,(2011) , 10.2165/11594170-000000000-00000
Lina Yin, Simon Lucas, Frauke Maurer, Uli Kazmaier, Qingzhong Hu, Rolf W. Hartmann, Novel Imidazol-1-ylmethyl Substituted 1,2,5,6-Tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as Potent and Selective CYP11B1 Inhibitors for the Treatment of Cushing’s Syndrome Journal of Medicinal Chemistry. ,vol. 55, pp. 6629- 6633 ,(2012) , 10.1021/JM3003872
Aditya Bardia, Erin T Arieas, Zhe Zhang, Andrew DeFilippis, Karineh Tarpinian, Stacie Jeter, Anne Nguyen, N Lynn Henry, David A Flockhart, Daniel F Hayes, Jill Hayden, Anna Maria Storniolo, Deborah K Armstrong, Nancy E Davidson, John Fetting, Pamela Ouyang, Antonio C Wolff, Roger S Blumenthal, M Dominique Ashen, Vered Stearns, None, Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Research and Treatment. ,vol. 131, pp. 907- 914 ,(2012) , 10.1007/S10549-011-1843-1
Qingzhong Hu, Lina Yin, Rolf W. Hartmann, Selective Dual Inhibitors of CYP19 and CYP11B2: Targeting Cardiovascular Diseases Hiding in the Shadow of Breast Cancer Journal of Medicinal Chemistry. ,vol. 55, pp. 7080- 7089 ,(2012) , 10.1021/JM3004637
Hylton V. Joffe, Gail K. Adler, Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Failure Reviews. ,vol. 10, pp. 31- 37 ,(2005) , 10.1007/S10741-005-2346-0
Qingzhong Hu, Lina Yin, Carsten Jagusch, Ulrike E. Hille, Rolf W. Hartmann, Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors. Journal of Medicinal Chemistry. ,vol. 53, pp. 5049- 5053 ,(2010) , 10.1021/JM100400A
Michael S. Ewer, Stefan Glück, A woman's heart Cancer. ,vol. 115, pp. 1813- 1826 ,(2009) , 10.1002/CNCR.24219
Steven A. Crone, You-Yang Zhao, Lian Fan, Yusu Gu, Susumu Minamisawa, Yang Liu, Kirk L. Peterson, Ju Chen, Ronald Kahn, Gianluigi Condorelli, John Ross Jr, Kenneth R. Chien, Kuo-Fen Lee, ErbB2 is essential in the prevention of dilated cardiomyopathy Nature Medicine. ,vol. 8, pp. 459- 465 ,(2002) , 10.1038/NM0502-459
Qingzhong Hu, Carsten Jagusch, Ulrike E. Hille, Jörg Haupenthal, Rolf W. Hartmann, Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer. Journal of Medicinal Chemistry. ,vol. 53, pp. 5749- 5758 ,(2010) , 10.1021/JM100317B